Yoshiaki Okamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoshiaki Okamoto has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Etsuko Uejima
Clinical Pharmacy Research and Education, Osaka University Graduate School of Pharmaceutical Sciences, Suita, Japan
5 shared publicationsSatoru Tsuneto
Department of Palliative Medicine, Kyoto University Hospital, Kyoto, Japan
5 shared publicationsHitoshi Tanimukai
Osaka University Hospital
3 shared publicationsMamiko Tsugane
Osaka University Hospital
3 shared publicationsYoichi Matsuda
Osaka University Hospital
3 shared publications- Hitoshi Tanimukai
Department of Psychiatric and Mental Health Nursing, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
2 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published byĀ Springer NatureĀ inĀ Supportive Care in Cancer
- Vol.Ā 34 Ā (12)
Dynamic taskābased rehabilitation and time to loss of toilet ambulation in a palliative care unit: a retrospective cohort study
Purpose: To determine whether dynamic-task rehabilitation, compared with bedside-only or no rehabilitation, is associated with longer time to loss of toilet ambulation among patients with advanced cancer in a palliative care unit (PCU). Methods: This retrospective study included patients with cancer admitted to a PCU who died during hospitalization (January 2020āMarch 2024). Eligible patients had walked to an in-room fixed toilet and stayed ā„ 14 days. Patients were classified as dynamic-task rehabilitation (Ex; ā„ 2 sessions), bedside rehabilitation (BS; ⤠1 dynamic-task session), or no rehabilitation (NI). The primary outcome was time from PCU admission to loss of toilet ambulation. KaplanāMeier and multivariable Cox analyses were used; FineāGray analyses treated death as a competing event. Results: A total of 205 patients were analyzed (Ex, n = 78; BS, n = 65; NI, n = 62). Median time to loss of toilet ambulation was 27 days in Ex, 20 days in BS, and 14 days in NI. In adjusted Cox models (NI reference), Ex was associated with a lower hazard of ambulation loss (HR, 0.462; 95% CI, 0.320ā0.667), whereas BS was not (HR, 0.828; 95% CI, 0.559ā1.226). Results were consistent in competing-risk analyses (Ex vs NI: sHR, 0.461; 95% CI, 0.328ā0.647). Conclusion: Patients able to receive dynamic-task rehabilitation had a longer time to loss of toilet ambulation during PCU hospitalization. This association may reflect rehabilitation content, patient characteristics, and the clinical feasibility of dynamic-task rehabilitation. Prospective studies are needed to clarify causality.
- 7 November 2026
- Published byĀ Springer NatureĀ inĀ Supportive Care in Cancer
- Vol.Ā 34 Ā (12)
Open AccessDynamic taskābased rehabilitation and time to loss of toilet ambulation in a palliative care unit: a retrospective cohort study
Purpose: To determine whether dynamic-task rehabilitation, compared with bedside-only or no rehabilitation, is associated with longer time to loss of toilet ambulation among patients with advanced cancer in a palliative care unit (PCU). Methods: This retrospective study included patients with cancer admitted to a PCU who died during hospitalization (January 2020āMarch 2024). Eligible patients had walked to an in-room fixed toilet and stayed ā„ 14 days. Patients were classified as dynamic-task rehabilitation (Ex; ā„ 2 sessions), bedside rehabilitation (BS; ⤠1 dynamic-task session), or no rehabilitation (NI). The primary outcome was time from PCU admission to loss of toilet ambulation. KaplanāMeier and multivariable Cox analyses were used; FineāGray analyses treated death as a competing event. Results: A total of 205 patients were analyzed (Ex, n = 78; BS, n = 65; NI, n = 62). Median time to loss of toilet ambulation was 27 days in Ex, 20 days in BS, and 14 days in NI. In adjusted Cox models (NI reference), Ex was associated with a lower hazard of ambulation loss (HR, 0.462; 95% CI, 0.320ā0.667), whereas BS was not (HR, 0.828; 95% CI, 0.559ā1.226). Results were consistent in competing-risk analyses (Ex vs NI: sHR, 0.461; 95% CI, 0.328ā0.647). Conclusion: Patients able to receive dynamic-task rehabilitation had a longer time to loss of toilet ambulation during PCU hospitalization. This association may reflect rehabilitation content, patient characteristics, and the clinical feasibility of dynamic-task rehabilitation. Prospective studies are needed to clarify causality.
- 21 September 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ Japanese Journal of Clinical Oncology
The 2025 revision of JPOS/JASCC clinical guidelines for delirium in adult patients with cancer: a summary of recommendations
Background: The Japan Psycho-Oncology Society and the Japanese Association of Supportive Care in Cancer revised the clinical practice guidelines for delirium in adult patients with cancer in 2025. In this article, we describe the guideline revision and summarize the updated recommendations. Methods: These guidelines were developed in accordance with the Minds Manual for Clinical Practice Guideline Development 2020. The multidisciplinary guideline development group formulated four new clinical questions (CQs) addressing delirium prevention (ramelteon and orexin receptor antagonists) and management (combination therapies of antipsychotics with either benzodiazepines or antihistamines). In addition, systematic reviews of 11 existing CQs were updated. Results: Multicomponent interventions were strongly recommended for delirium prevention, based on moderate-certainty evidence. Bright light therapy, antipsychotics, ramelteon, and orexin receptor antagonists were not recommended for prevention. For delirium management, antipsychotics, trazodone, the combination of antipsychotics and benzodiazepines, and opioid switching were suggested, whereas hydroxyzine, benzodiazepines alone, and the combination of antipsychotics and antihistamines were not recommended. All recommendations for delirium management were weak, with low- to very-low-certainty evidence. Background questions addressed delirium assessment tools, precipitating factors, non-pharmacological interventions, and interventions for terminally ill patients. Conclusions: These revised clinical practice guidelines can serve as a practical framework for optimizing prevention, assessment, and management of delirium in adult patients with cancer in Japan.
- 21 September 2026
- Published byĀ Oxford University Press (OUP)Ā inĀ Japanese Journal of Clinical Oncology
The 2025 revision of JPOS/JASCC clinical guidelines for delirium in adult patients with cancer: a summary of recommendations
Background: The Japan Psycho-Oncology Society and the Japanese Association of Supportive Care in Cancer revised the clinical practice guidelines for delirium in adult patients with cancer in 2025. In this article, we describe the guideline revision and summarize the updated recommendations. Methods: These guidelines were developed in accordance with the Minds Manual for Clinical Practice Guideline Development 2020. The multidisciplinary guideline development group formulated four new clinical questions (CQs) addressing delirium prevention (ramelteon and orexin receptor antagonists) and management (combination therapies of antipsychotics with either benzodiazepines or antihistamines). In addition, systematic reviews of 11 existing CQs were updated. Results: Multicomponent interventions were strongly recommended for delirium prevention, based on moderate-certainty evidence. Bright light therapy, antipsychotics, ramelteon, and orexin receptor antagonists were not recommended for prevention. For delirium management, antipsychotics, trazodone, the combination of antipsychotics and benzodiazepines, and opioid switching were suggested, whereas hydroxyzine, benzodiazepines alone, and the combination of antipsychotics and antihistamines were not recommended. All recommendations for delirium management were weak, with low- to very-low-certainty evidence. Background questions addressed delirium assessment tools, precipitating factors, non-pharmacological interventions, and interventions for terminally ill patients. Conclusions: These revised clinical practice guidelines can serve as a practical framework for optimizing prevention, assessment, and management of delirium in adult patients with cancer in Japan.
- 7 October 2025
- Published byĀ ElsevierĀ inĀ Journal of the Academy of Consultation-Liaison Psychiatry
- Vol.Ā 67 Ā (1) , 35-47
Quality Indicators in Psychological Care for Patients With Serious Illness: A Systematic Review
- 7 October 2025
- Published byĀ ElsevierĀ inĀ Journal of the Academy of Consultation-Liaison Psychiatry
- Vol.Ā 67 Ā (1) , 35-47
Quality Indicators in Psychological Care for Patients With Serious Illness: A Systematic Review
- Open Access
- 26 September 2023
- Published byĀ ElsevierĀ inĀ Journal of Pain and Symptom Management
- Vol.Ā 67 Ā (1) , 39-49.e5
Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study
- 26 September 2023
- Published byĀ ElsevierĀ inĀ Journal of Pain and Symptom Management
- Vol.Ā 67 Ā (1) , 39-49.e5
Open AccessComparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study
- Open Access
- 11 August 2021
- Published byĀ ElsevierĀ inĀ Clinical and Translational Radiation Oncology
- Vol.Ā 30, 88-94
Long-term outcomes of an esophagus-preserving chemoradiotherapy strategy for patients with endoscopically unresectable stage I thoracic esophageal squamous cell carcinoma
- 11 August 2021
- Published byĀ ElsevierĀ inĀ Clinical and Translational Radiation Oncology
- Vol.Ā 30, 88-94
Open AccessLong-term outcomes of an esophagus-preserving chemoradiotherapy strategy for patients with endoscopically unresectable stage I thoracic esophageal squamous cell carcinoma
- 2 April 2018
- Published byĀ SAGE PublicationsĀ inĀ American Journal of Hospice and Palliative MedicineĀ®
- Vol.Ā 35 Ā (7) , 972-977
Bereaved Family Membersā Perceptions of the Distressing Symptoms of Terminal Patients With Cancer
Background: Few data are available on bereaved family membersā perspective on the frequency of symptoms and degree of distress among terminal patients with cancer. Methods: We sent a questionnaire to 1472 bereaved family members of terminal patients with cancer in 20 general hospitals. The questionnaire asked them (1) to indicate which symptoms the patients had, (2) to rate on a 4-point scale the extent to which the symptom was distressing, as follows: 1 = not distressing, 2 = slightly distressing, 3 = quite distressing, and 4 = very distressing at the point of 2 weeks before the patient had died. Results: We analyzed 805 questionnaires for this study. Anorexia was the commonest symptom among terminal patients with cancer experienced by bereaved family members, followed by somnolence, weight loss, fatigue, and pain. Anorexia was the most distressing symptom among terminal patients with cancer experienced by bereaved family members, followed by weight loss, pain, edema, and dyspnea. Conclusions: Anorexia and weight loss were frequent symptoms and bereaved family members felt very distressing. Furthermore, there are not means of effective treatment now. Thus, we think that further study in this field is necessary.
- 2 April 2018
- Published byĀ SAGE PublicationsĀ inĀ American Journal of Hospice and Palliative MedicineĀ®
- Vol.Ā 35 Ā (7) , 972-977
Bereaved Family Membersā Perceptions of the Distressing Symptoms of Terminal Patients With Cancer
Background: Few data are available on bereaved family membersā perspective on the frequency of symptoms and degree of distress among terminal patients with cancer. Methods: We sent a questionnaire to 1472 bereaved family members of terminal patients with cancer in 20 general hospitals. The questionnaire asked them (1) to indicate which symptoms the patients had, (2) to rate on a 4-point scale the extent to which the symptom was distressing, as follows: 1 = not distressing, 2 = slightly distressing, 3 = quite distressing, and 4 = very distressing at the point of 2 weeks before the patient had died. Results: We analyzed 805 questionnaires for this study. Anorexia was the commonest symptom among terminal patients with cancer experienced by bereaved family members, followed by somnolence, weight loss, fatigue, and pain. Anorexia was the most distressing symptom among terminal patients with cancer experienced by bereaved family members, followed by weight loss, pain, edema, and dyspnea. Conclusions: Anorexia and weight loss were frequent symptoms and bereaved family members felt very distressing. Furthermore, there are not means of effective treatment now. Thus, we think that further study in this field is necessary.
- 10 July 2016
- Published byĀ SAGE PublicationsĀ inĀ American Journal of Hospice and Palliative MedicineĀ®
- Vol.Ā 34 Ā (3) , 248-253
Desirable Information of Opioids for Families of Patients With Terminal Cancer
Objective: The aims of this study are to clarify the state of information regarding opioids for families and what kinds of experiences they had with opioids while the patient was followed as an outpatient and inpatient. Participants: This study was part of a cross-sectional nationwide survey of bereaved families of patients with cancer, namely, the Japan Hospice and Palliative Care Evaluation 2 study. The participants in this study comprised 572 bereaved families who had experienced the death of a family member during the period from January 2008 to December 2009 at 1 of 103 certificated palliative care units. Main Outcome Measures: In response to the question of āhow much improvement was needed for information regarding opioids,ā 41% answered āimprovement is not necessary at all,ā 43% answered āimprovement is slightly necessary,ā 14% answered āimprovement is necessary,ā and 2% answered āimprovement is extremely necessary.ā Regarding anxiety about the use of opioid, it was found that 14% of respondents indicated āopioids are very safe,ā 65% of respondents indicated āopioids are relatively safe,ā 19% of respondents indicated āopioids are not so safe,ā and 2% of respondents indicated āopioids are not so safe at all.ā from the information obtained for opioids. It was found that 90% of families agreed with the item, āI would like to be clearly explained that drugs for medical purposes are safe and that the patient will not develop a drug addiction and their life expectancy will not be reduced.ā Conclusion: From this study, it is important for families of patients with cancer to be explained profound and careful information of opioid.
- 10 July 2016
- Published byĀ SAGE PublicationsĀ inĀ American Journal of Hospice and Palliative MedicineĀ®
- Vol.Ā 34 Ā (3) , 248-253
Desirable Information of Opioids for Families of Patients With Terminal Cancer
Objective: The aims of this study are to clarify the state of information regarding opioids for families and what kinds of experiences they had with opioids while the patient was followed as an outpatient and inpatient. Participants: This study was part of a cross-sectional nationwide survey of bereaved families of patients with cancer, namely, the Japan Hospice and Palliative Care Evaluation 2 study. The participants in this study comprised 572 bereaved families who had experienced the death of a family member during the period from January 2008 to December 2009 at 1 of 103 certificated palliative care units. Main Outcome Measures: In response to the question of āhow much improvement was needed for information regarding opioids,ā 41% answered āimprovement is not necessary at all,ā 43% answered āimprovement is slightly necessary,ā 14% answered āimprovement is necessary,ā and 2% answered āimprovement is extremely necessary.ā Regarding anxiety about the use of opioid, it was found that 14% of respondents indicated āopioids are very safe,ā 65% of respondents indicated āopioids are relatively safe,ā 19% of respondents indicated āopioids are not so safe,ā and 2% of respondents indicated āopioids are not so safe at all.ā from the information obtained for opioids. It was found that 90% of families agreed with the item, āI would like to be clearly explained that drugs for medical purposes are safe and that the patient will not develop a drug addiction and their life expectancy will not be reduced.ā Conclusion: From this study, it is important for families of patients with cancer to be explained profound and careful information of opioid.
- 1 November 2012
- Published byĀ SAGE PublicationsĀ inĀ Journal of Palliative Medicine
- Vol.Ā 15 Ā (11) , 1185-1190
A Retrospective Chart Review of Terminal Patients with Cancer with Agitation and Their Risk Factors
Background: Agitated delirium is often observed in terminal patients with cancer. To clarify the risk factors for agitated delirium in terminal patients with cancer, we conducted a retrospective chart review of 126 patients with cancer who died at a university hospital in 2008. Method: As a working definition, we define agitated delirium as a score of 2 or more in item 9 of the Memorial Delirium Assessment Scale with diurnal variation. Results: The results were as follows: agitated delirium was observed in 49 (42%) of the 115 patients, and it occurred within the last week before death in 49% of the patients. Univariate analysis revealed older age, male gender, smoking history, lung cancer, diabetes, and high C-reactive protein (CRP) value as major risk factors, while dendritic analysis revealed lung cancer, high CRP value, diabetes, older age, and smoking history as key factors for predicting agitation. Conclusion: It is necessary to consider risk factors in order to categorize terminal patients with cancer into high- and low-risk groups and undertake possible counter-measures.
- 1 November 2012
- Published byĀ SAGE PublicationsĀ inĀ Journal of Palliative Medicine
- Vol.Ā 15 Ā (11) , 1185-1190
A Retrospective Chart Review of Terminal Patients with Cancer with Agitation and Their Risk Factors
Background: Agitated delirium is often observed in terminal patients with cancer. To clarify the risk factors for agitated delirium in terminal patients with cancer, we conducted a retrospective chart review of 126 patients with cancer who died at a university hospital in 2008. Method: As a working definition, we define agitated delirium as a score of 2 or more in item 9 of the Memorial Delirium Assessment Scale with diurnal variation. Results: The results were as follows: agitated delirium was observed in 49 (42%) of the 115 patients, and it occurred within the last week before death in 49% of the patients. Univariate analysis revealed older age, male gender, smoking history, lung cancer, diabetes, and high C-reactive protein (CRP) value as major risk factors, while dendritic analysis revealed lung cancer, high CRP value, diabetes, older age, and smoking history as key factors for predicting agitation. Conclusion: It is necessary to consider risk factors in order to categorize terminal patients with cancer into high- and low-risk groups and undertake possible counter-measures.
- 24 July 2012
- Published byĀ SAGE PublicationsĀ inĀ American Journal of Hospice and Palliative MedicineĀ®
- Vol.Ā 30 Ā (5) , 450-454
Can Gradual Dose Titration of Ketamine for Management of Neuropathic Pain Prevent Psychotomimetic Effects in Patients With Advanced Cancer?
Ketamine is often used to manage neuropathic pain in patients with cancer. However, it occasionally causes psychotomimetic effects such as vivid dreams, nightmares, illusions, hallucinations, and altered body image. Objective: To examine whether gradual dose titration of ketamine for management of neuropathic pain prevents psychotomimetic effects in patients with advanced cancer. This was a retrospective chart review. We administered ketamine when neuropathic pain in patients with advanced cancer became refractory to opioids and oral adjuvant analgesics. The starting dose of ketamine was 10 mg/d by continuous intravenous infusion. The dose was gradually increased by 10 mg/d every 4 to 6 hours to 50 mg/d or until the pain was relieved. It was subsequently increased by 25 mg/d every 12 to 24 hours until the pain was relieved. For this study, we enrolled 46 patients with advanced cancer. The mean age was 52.2 ± 16.9 years. The mean dose at onset of action and maximum dose of ketamine were 56 ± 58 and 272 ± 214 mg/d, respectively. The mean pain intensity (numerical rating scale) decreased significantly from 7.3 ± 2.0 to 3.5 ± 2.2 after the administration of ketamine (P < .01). The effectiveness was 69.5%. No psychotomimetic effect of less than 300 mg/d was observed during the introduction phase even though psychotropic drugs were not prescribed. Mild sedation was observed in 3 patients (7%) as the only adverse effect during the introduction phase. Gradual dose titration of ketamine for management of neuropathic pain can prevent psychotomimetic effects in patients with advanced cancer.
- 24 July 2012
- Published byĀ SAGE PublicationsĀ inĀ American Journal of Hospice and Palliative MedicineĀ®
- Vol.Ā 30 Ā (5) , 450-454
Can Gradual Dose Titration of Ketamine for Management of Neuropathic Pain Prevent Psychotomimetic Effects in Patients With Advanced Cancer?
Ketamine is often used to manage neuropathic pain in patients with cancer. However, it occasionally causes psychotomimetic effects such as vivid dreams, nightmares, illusions, hallucinations, and altered body image. Objective: To examine whether gradual dose titration of ketamine for management of neuropathic pain prevents psychotomimetic effects in patients with advanced cancer. This was a retrospective chart review. We administered ketamine when neuropathic pain in patients with advanced cancer became refractory to opioids and oral adjuvant analgesics. The starting dose of ketamine was 10 mg/d by continuous intravenous infusion. The dose was gradually increased by 10 mg/d every 4 to 6 hours to 50 mg/d or until the pain was relieved. It was subsequently increased by 25 mg/d every 12 to 24 hours until the pain was relieved. For this study, we enrolled 46 patients with advanced cancer. The mean age was 52.2 ± 16.9 years. The mean dose at onset of action and maximum dose of ketamine were 56 ± 58 and 272 ± 214 mg/d, respectively. The mean pain intensity (numerical rating scale) decreased significantly from 7.3 ± 2.0 to 3.5 ± 2.2 after the administration of ketamine (P < .01). The effectiveness was 69.5%. No psychotomimetic effect of less than 300 mg/d was observed during the introduction phase even though psychotropic drugs were not prescribed. Mild sedation was observed in 3 patients (7%) as the only adverse effect during the introduction phase. Gradual dose titration of ketamine for management of neuropathic pain can prevent psychotomimetic effects in patients with advanced cancer.
- Open Access
- 1 October 2010
- Published byĀ Pharmaceutical Society of JapanĀ inĀ YAKUGAKU ZASSHI
- Vol.Ā 130 Ā (10) , 1369-1374
Light-induced Deterioration Test of Carboplatin under Clinical Settings
Chemotherapeutic drug dosages are calculated precisely based on the patient's height, body weight, and renal function, etc. To ensure safe and favorable outcomes of treatment, dosing solutions are prepared by appropriate mixing of the drug solutions based on such calculations. The package inserts for many injectable preparations include a warning for storing the product āshielded from light.ā However, there are no reports of stability assessment of a mixed product against light exposure or the residual amount of active ingredient in the dosing solution during or at the end of treatment. We evaluated the stability of carboplatin from the time of mixing of the dosing solution until the end of drug infusion in a clinical-like setting. With 4-hour exposure to outdoor scattered light, the dosing solution began to show discoloration by 1 hour, becoming dark yellow by 4 hours, with reduction of the percent residual carboplatin to about 23%. To identify the optimal light-shielding shade, the dosing solution was shielded from outdoor scattered light with 1 of 3 protective covers: aluminum foil, yellow plastic shade, and brown plastic shade. The yellow plastic shade prevented any changes of the appearance of the dosing solution during the 4-hour exposure period. The percent residual carboplatin, determined by HPLC, in the dosing solution shielded with a yellow plastic shade was about 85.2% at 2 hours and 78.6% at 4 hours. Thus carboplatin dosing solution should be completely shielded from light until infusion is completed.
- 1 October 2010
- Published byĀ Pharmaceutical Society of JapanĀ inĀ YAKUGAKU ZASSHI
- Vol.Ā 130 Ā (10) , 1369-1374
Open AccessLight-induced Deterioration Test of Carboplatin under Clinical Settings
Chemotherapeutic drug dosages are calculated precisely based on the patient's height, body weight, and renal function, etc. To ensure safe and favorable outcomes of treatment, dosing solutions are prepared by appropriate mixing of the drug solutions based on such calculations. The package inserts for many injectable preparations include a warning for storing the product āshielded from light.ā However, there are no reports of stability assessment of a mixed product against light exposure or the residual amount of active ingredient in the dosing solution during or at the end of treatment. We evaluated the stability of carboplatin from the time of mixing of the dosing solution until the end of drug infusion in a clinical-like setting. With 4-hour exposure to outdoor scattered light, the dosing solution began to show discoloration by 1 hour, becoming dark yellow by 4 hours, with reduction of the percent residual carboplatin to about 23%. To identify the optimal light-shielding shade, the dosing solution was shielded from outdoor scattered light with 1 of 3 protective covers: aluminum foil, yellow plastic shade, and brown plastic shade. The yellow plastic shade prevented any changes of the appearance of the dosing solution during the 4-hour exposure period. The percent residual carboplatin, determined by HPLC, in the dosing solution shielded with a yellow plastic shade was about 85.2% at 2 hours and 78.6% at 4 hours. Thus carboplatin dosing solution should be completely shielded from light until infusion is completed.